Incyte saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 80 to 83.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating north of 80 as they begin their biggest runs.
Incyte is working on a consolidation with an 83.95 entry. See if the stock can clear the breakout price in heavy trade.
The company posted 0% EPS growth in its most recent report, while sales growth came in at 16%.
The company earns the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
